Merck's 15-strain flu shot matches Prevnar 13 in late-stage infant study, but Pfizer's next-gen shot looms

Merck’s Vaxneuvance, a next-gen, 15-valent flu shot, matched Pfizer’s blockbuster Prevnar 13 in terms of driving immunogenicity across 13 shared serotypes and on the safety front, according to data from the Phase III PNEU-PED study revealed Wednesday.